At ASCO GI 2025, Yelena Janjigian and colleagues presented DESTINY-Gastric03 (DG-03) trial results, evaluating trastuzumab deruxtecan (T-DXd) with fluoropyrimidine (FP) and pembrolizumab as first-line therapy for advanced HER2+ gastric, esophageal, and gastroesophageal junction cancer.
Key findings:
T-DXd 5.4 mg/kg had a higher ORR (59.4%) than 6.4 mg/kg (41.9%), with no efficacy loss
Median PFS: 6.4 months (6.4 mg/kg) vs. 5.8 months (5.4 mg/kg)
Lower dosing improved tolerability while maintaining strong clinical activity
Under Dr. Janjigian’s leadership, this study supports T-DXd 5.4 mg/kg as a potential new first-line standard, balancing efficacy and safety.
Acknowledgment to Hanneke van Laarhoven, Sun Young Rha, Vadim Kozlov, Do-Youn Oh, Adriano Gravina, and the entire team for their contributions.
Read the full study here: https://lnkd.in/euMBrRkx
